Fenofibrate just as good for women with diabetes as for men

The researchers from the universities of Sydney, Queensland and Melbourne said their findings should allay concerns about the use of fenofibrate in women raised by the ACCORD study, which suggested women may not gain benefit from the drug with regard to cardiovascular event reduction. 

The finding prompted the US Food and Drug Administration to issue a safety warning about the use of the drug.

According to Professor Alicia Jenkins from the NHMRC Clinical Trials Centre, a co-author of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, their cohort was much larger than that of ACCORD and so is able to provide more data and statistical power to properly assess the concerns. 

More than 3600 women and 6000 men with type 2 diabetes who were not on statins were randomly assigned fenofibrate (200mg/day) or placebo for five years, and the effect on lipoproteins and total cardiovascular events were evaluated by sex.